Veracyte Announces That New Guidelines Include Molecular Testing For Indeterminate Thyroid Nodules To Reduce Unnecessary Surgeries
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2013 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that, for the first time, molecular testing is now included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Thyroid Carcinoma. The new NCCN Guidelines indicate that, when a thyroid nodule fine needle aspiration (FNA) result is indeterminate using traditional cytopathology, which relies on microscope-based review, physicians should consider using molecular testing in lieu of diagnostic surgery, provided the test's performance is similar in accuracy to a benign diagnosis using cytopathology. This new approach could enable tens of thousands of patients to avoid surgery to remove all or part of their thyroids for diagnosis. The NCCN is an alliance of 21 world-leading cancer centers. The new guidelines are published online at www.nccn.org.
Veracyte's Afirma® Gene Expression Classifier test demonstrated in a multicenter, prospective validation study, published recently in the New England Journal of Medicine, that when it reclassified thyroid nodule FNA samples that were initially deemed indeterminate by cytopathology as benign – which it did more than 50% of the time – its accuracy was similar to a benign diagnosis using cytopathology.
"We are pleased that NCCN, a leader in establishing evidence-based, high-quality cancer diagnosis and management, has recommended the use of molecular testing to replace surgery to address the clinical problem of inconclusive thyroid nodule results," said Bonnie Anderson, cofounder and CEO of Veracyte. "Their recommendation reinforces the growing use of the Afirma Gene Expression Classifier by endocrinologists around the country to help many patients safely avoid unnecessary thyroid surgeries."
Approximately 450,000 thyroid nodule FNAs – a minimally invasive procedure to extract cells for examination under the microscope – are performed each year in the U.S. to rule out cancer. In 15-30% of cases, the results are indeterminate, or not clearly benign or malignant, and current protocols typically recommend thyroid surgery for final diagnosis. Following surgery, however, most (70-80%) patients turn out to have benign nodules.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV